Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
Mizuno K, Inoue T, Kinoshita H, Yano T, Kawanishi H, Kanda H, Terada N, Kobayashi T, Kamba T, Mikami Y, Shiraishi T, Uemura Y, Imai Y, Honjo G, Shirase T, Okumura K, Kawakita M, Ogura K, Sugimura Y, Matsuda T, Ogawa O. Mizuno K, et al. Jpn J Clin Oncol. 2016 Dec;46(12):1156-1161. doi: 10.1093/jjco/hyw130. Epub 2016 Oct 15. Jpn J Clin Oncol. 2016. PMID: 27744325
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, Li X, Utsunomiya N, Goto T, Kobayashi T, Terada N, Inoue T, Kamba T, Fujimoto A, Ogawa O, Akamatsu S. Sumiyoshi T, et al. Among authors: mizuno k. Sci Rep. 2019 Mar 11;9(1):4030. doi: 10.1038/s41598-019-40719-y. Sci Rep. 2019. PMID: 30858508 Free PMC article.
Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.
Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, Terada N, Kobayashi T, Yamasaki T, Inoue T, Tsuchiya N, Ohyama C, Arai Y, Habuchi T, Morita S, Ogawa O. Akamatsu S, et al. Among authors: mizuno k. Eur Urol Oncol. 2019 May;2(3):320-328. doi: 10.1016/j.euo.2018.10.011. Epub 2018 Nov 23. Eur Urol Oncol. 2019. PMID: 31200847
Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O. Fujiwara M, et al. Among authors: mizuno k. Clin Genitourin Cancer. 2019 Oct;17(5):e923-e929. doi: 10.1016/j.clgc.2019.04.017. Epub 2019 Jun 12. Clin Genitourin Cancer. 2019. PMID: 31307917
3,190 results